Scientists weaponize Patients' own cells to attack Virus-Linked cancer
NCT ID NCT04509726
Summary
This early-stage trial tested whether specially engineered immune cells could fight a type of head and neck cancer linked to Epstein-Barr virus. Researchers modified patients' own T-cells to recognize and attack cancer cells carrying the virus. The study involved 9 people with advanced or returning nasopharyngeal cancer to find the safest dose of these engineered cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Oncology, Xinqiao Hospital
Chongqing, Chongqing Municipality, 400037, China
Conditions
Explore the condition pages connected to this study.